Secukinumab
COSENTYX
Interleukin-17A Antagonist
NADAC/unit
$3950.7728
No Shortage
Tier 1: 57.1%
PA Req: 313.7%
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for sy....
vs. brand COSENTYX: Generic saves up to -39408% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.